The implementation of aducanumab, the drug minimizing the symptoms of Alzheimer’s, has significant risks of disturbing the whole medical insurance system. Primarily the problem is related to the Medicaid problem. Medicaid covers the enormous costs for this drug on the 25 percent while the remaining amount of money patients should pay themselves. Despite this, even the small percent coverage may damage the whole system of healthcare budgeting. The insurance system is at significant risk of being distorted in a short time period. Thus, the heal care industry of the edge of important changes related to the approval of this drug, which may even cause new healthcare reforms.
The stakeholders are also at significant risk of being affected by the approval of the aducanumab. Their problems are primarily related to the issue of the federal pricing reforms needs. The significant financial changes in this sphere may cause enormous losses for the stakeholders due to rapid changes. Various healthcare organizations, usually the influential stakeholders in the healthcare sphere, may be significantly affected because their investments will not be realized as expected. Due to the extremely high expenses on this drug’s support, design, production, and implementation, the other vital problems requiring budgeting will be left unsolved. The lack of budgeting will cause issues with health research due to the lack of budgeting. The stakeholders’ expenditures will be increased to sustain at least the normal quality of healthcare. The implementation of the drug, despite its practical importance, seems exaggerated and too rapid. Therefore, from the economic perspective, its approval is irrational, potentially harming the whole healthcare system’s development due to the financial difficulties for the stakeholders and insurance inquiries.